Small molecule · developed by Anavex Life Sciences
ANAVEX2-73 is an oral drug given as 30 mg and 50 mg hard gelatin capsules. It is studied in Alzheimer's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03790709 | Phase 2/3 | Alzheimer Disease | Completed | AVXL |
| NCT02244541 | Phase 2 | Alzheimer's Disease | Completed | AVXL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseaseAlzheimer's Disease
Updated Nov 8, 2026. Something wrong or missing? Report it on the AVXL page.
See AVXL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVXL catalysts and pipeline →